《美股》HIV藥大廠吉利德科學(GILD.US)次季盈利勝預期 上調全年盈測 盤前升近3%
HIV預防及治療藥巨擘吉利德科學(Gilead Sciences)(GILD.US)公布2025年第二季財報,總收入按年增2%至71億美元,符市場預期,主要受HIV藥物Biktarvy、Descovy、Trodelvy及Livdelzi銷售增長推動,惟慢性丙型肝炎藥物及Veklury銷售下跌抵銷部分增幅。次季剔除Veklury的產品銷售按年增4%至69億美元,其中Biktarvy銷售額升9%至35億美元。總HIV相關產品銷售按年升7%至51億美元。
公司錄得每股攤薄盈利1.56美元,較去年同期的1.29美元增長,主要受證券未實現收益及產品銷售增加帶動,惟部分被1,900萬美元的研發資產減值及研發費用上升抵銷。非公認會計準則每股攤薄盈利為2.01美元,與去年同期持平,並勝市場預期的每股1.97美元。
截至2025年6月底,公司持有現金、現金等價物及有價證券71億美元,第二季經營現金流為8.27億美元。公司於季內支付股息9.94億美元,並回購5.27億美元普通股。
公司預期全年收入及盈利指引上調,料全年經調整每股盈利介乎7.95至8.25美元,高於原先介乎7.7至8.1美元,市場料每股8.01美元;亦上調產品銷售預測至介乎283億至287億美元,高於原先介乎282億至286億美元,市場料287億美元,並持續推進核心治療領域的創新及增長。
該股盤前交易時段升2.9%,報113.47美元。~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.